Clinical Trials Logo

Coronary Artery Disease clinical trials

View clinical trials related to Coronary Artery Disease.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03231059 Active, not recruiting - Clinical trials for Coronary Artery Disease

GLOBAL LEADERS Adjudication Sub-Study

GLASSY
Start date: June 1, 2017
Phase: N/A
Study type: Observational

The GLOBAL LEADERS Adjudication Sub-StudY, GLASSY, is based on a re-assessment of all the events reported in the dataset of the parent trial (COMPARATIVE EFFECTIVENESS OF 1 MONTH OF TICAGRELOR PLUS ASPIRIN FOLLOWED BY TICAGRELOR MONOTHERAPY VERSUS A CURRENT-DAY INTENSIVE DUAL ANTIPLATELET THERAPY IN ALL-COMERS PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION WITH BIVALIRUDIN AND BIOMATRIX FAMILY DRUG-ELUTING STENT USE) by an independent Clinical Event Committee (CEC), composed of three physicians not involved in the main trial. The substudy include the first 19 top-enrolling sites of the GLOBAL LEADERS to reach the estimated sample size of 7,186 patients for the two co-primary outcomes of death, any non-fatal myocardial infarction, any non-fatal stroke or urgent target vessel revascularization and bleeding events classified as 3 or 5 according to the Bleeding Academic Research Consortium (BARC) criteria. To ensure a comprehensive assessment of clinical events, a triggers logic is adopted to identify other potential events qualifying for study endpoints but not reported as such by local investigators.

NCT ID: NCT03221127 Active, not recruiting - Depression Clinical Trials

Kuopio Ischaemic Heart Disease Risk Factor Study (Nutrition Component)

Start date: March 1, 1984
Phase: N/A
Study type: Observational

To determine associations between dietary factors and risk of major chronic diseases and their risk factors

NCT ID: NCT03206333 Active, not recruiting - Breast Cancer Clinical Trials

Automated Quantification of Coronary Artery Calcifications on Radiotherapy Planning CTs for Cardiovascular Risk Prediction in Breast Cancer Patients: the BRAGATSTON Study

Start date: January 1, 2017
Phase: N/A
Study type: Observational

The aim of the BRAGATSTON study is to provide a low cost tool for measuring CAC in breast cancer patients, thereby identifying patients at increased risk of CVD. Breast cancer patients and doctors can act upon this, by adapting the treatment and/or by adopting cardioprotective interventions. Hereby, the burden of CVD in breast cancer survivors can be reduced and better overall survival rates can be achieved.

NCT ID: NCT03194711 Active, not recruiting - Coronary Disease Clinical Trials

BVS-OCT Imaging Study

Start date: May 30, 2017
Phase: N/A
Study type: Observational

The single center retrospective study evaluates the acute and long term outcomes of bioabsorbable drug-eluting scaffolds (BVS) implantation in 50 consecutive coronary artery disease (CAD) patients using optical coherence tomography (OCT) imaging.

NCT ID: NCT03192891 Active, not recruiting - Myocardial Ischemia Clinical Trials

Clinical Impact of Stress CMR Perfusion Imaging

SPINS
Start date: March 1, 2017
Phase: N/A
Study type: Observational

Numerous single-center studies have indicated gadolinium-enhanced stress CMR perfusion imaging has excellent diagnostic accuracy for coronary artery disease and negative clinical event rates, with its diagnostic accuracy exceeding nuclear scintigraphy. However, current prognostic evidence supporting clinical use of stress CMR is limited by study size, single-center settings with a predominance of academic centers, and a lack of "real-world" study design. Large-scale multicenter real-world evidence from a registry will provide the much needed information to guide evidence-based clinical adaptation that benefits patient care.

NCT ID: NCT03176810 Active, not recruiting - Coronary Disease Clinical Trials

Comparison Between Optimal Coherence Tomography Guidance and Angiography Guidance in Percutaneous Coronary Intervention

COCOA
Start date: April 1, 2017
Phase: N/A
Study type: Interventional

The present study aims to demonstrate the superiority of optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI) compared with Angiography-guided PCI.

NCT ID: NCT03159559 Active, not recruiting - Clinical trials for Coronary Microvascular Perfusion in Patients With Ischemic Heart Disease

PGE1 Improves Coronary Microcirculation Dysfunction in Patients With CAD and Diabetes

Start date: January 2017
Phase: Phase 4
Study type: Interventional

This study is undertaken to determine if intravenous Lipo-PGE1 therapy would improve coronary microvascular perfusion in patients with ischemic heart disease by CMRI.

NCT ID: NCT03133689 Active, not recruiting - Clinical trials for Coronary Heart Disease

Alcohol Consumption and Coronary Heart Disease Onset

Start date: March 1, 2017
Phase: N/A
Study type: Observational

The primary aim of this study is to examine if long-term patterns of alcohol consumption are associated with time-to-onset for incident coronary heart disease (fatal and non-fatal), using data from multiple cohorts.

NCT ID: NCT03118531 Active, not recruiting - Clinical trials for Coronary Artery Disease

China Resolute Integrity 34/38 mm Study

Start date: April 17, 2017
Phase: N/A
Study type: Interventional

To evaluate the clinical safety and efficacy in Chinese subjects, eligible for percutaneous transluminal coronary angioplasty (PTCA) in lesions amenable to treatment with a 34/38 mm Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System.

NCT ID: NCT03066141 Active, not recruiting - Clinical trials for Coronary Artery Disease

Evaluation of Association Between Obstructive Sleep Apnea and the Severity of Coronary Artery Disease

Start date: February 14, 2017
Phase: N/A
Study type: Observational [Patient Registry]

It is widely accepted that coronary artery disease (CAD) is related to a high mortality. It is predicted that an increase of approximately 21.3 million cardiovascular events and 7.7 million cardiovascular deaths over 2010 to 2030 in China.1 Male sex, diabetes mellitus, hypertension, hypercholesterolemia, obesity and smoking are all traditionally considered as risk factors for CAD. In recent decades, tremendous progress toward the prevention and treatment of traditional cardiovascular risk factors have helped decrease the morbidity and mortality from CAD, but the condition remains a major public health challenge worldwide. Looking into the other potential risk factors (OSA) for CAD, it may help to develop additional preventative strategies and further reduce the incidence and mortality of CAD.